May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana,...
Case Reports Of These Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Causing Diabetic Ketoacidosis (DKA) Presented At Recent Medical Meeting SUMMARY: The FDA is investigating a connection between...
View ArticleInvokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic...
This Ketoacidosis Side Effect For These New Diabetes Medicines Was The Subject Of A May 2015 FDA Drug Safety Warning Which Was, Perhaps, Not Strong Enough About Dangers SUMMARY: At the June 2015...
View ArticleFarxiga / Jardiance / Invokana: Ketoacidosis and Kidney Failure
SUMMARY: On June 22, 2015 Health Canada sent a MedEffect email alert about its “Information Update – Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors...
View ArticleInvokana Lawsuits Filed While FDA Investigates Side Effects Reports
SUMMARY: Invokana — first available in 2013 –is part of a new class of diabetes medications called Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, which also these drugs: Invokamet — first...
View ArticleDespite Benefits Of Jardiance, There Are Still Safety Concerns
Jardiance is part of the Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors class of diabetes drugs, which also includes Invokana and Farxiga. The financial analysts who focus on the pharmaceutical...
View ArticleInvokana Label Gets New Warnings About Increased Risk Of Bone Fractures
From this September 2015 FDA document, “Invokana and Invokamet (canagliflozin): Drug Safety Communication – New Information on Bone Fracture Risk and Decreased Bone Mineral Density”, we learned that...
View ArticleFDA Adds New Ketoacidosis Side Effect Warnings To Invokana Drug Label
In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract...
View ArticleEMA Says Invokana / Farxiga /Jardiance Linked To Diabetic Ketoacidosis
On February 12, 2016 the European Medicines Agency (EMA) issued a drug safety alert about the possibility of atypical cases of diabetic ketoacidosis (DKA) associated with Invokana, Farxiga, Jardiance,...
View ArticleInvokana Cases Involving Diabetic Ketoacidosis And Kidney Side Effects
According to data from IMS Health, Invokana reached 1.1 million dispensed outpatient prescriptions in the second quarter of 2015, followed by Farxiga with 411,000, and Jardiance with 136,000. These...
View ArticleWhen Used By Type 1 Diabetes Patients, Invokana Can Cause Ketoacidosis
Diabetic ketoacidosis (DKA) is a state of metabolic acidosis brought on primarily by insulin deficiency. The condition can affect patients with type 1 or type 2 diabetes. It is important to know that...
View ArticleStroke, DVT, Pulmonary Embolism, And Kidney Damage Linked To Invokana
We will be monitoring the medical literature for developments and watching for any forthcoming FDA action concerning the association of acute kidney / renal injury, thromboembolic events (e.g., DVTs,...
View ArticleInvokana / Farxiga / Jardiance: Amputations; Lactic Acidosis; Ketoacidosis
In July 2016 Boehringer Ingelheim Pharmaceuticals, Inc. received a Supplemental Approval letter from the FDA concerning a label change about fatal cases of ketoacidosis which have been reported...
View ArticleInvokana / Farxiga / Jardiance: UTIs Then Urosepsis And Pyelonephritis
To date, most attention has been directed to the association between the sodium-glucose cotransporter-2 (SGLT2) inhibitors drugs and diabetic ketoacidosis (DKA). More recently, there was an FDA...
View ArticleViagra, Nexium, And Invokana: Drug Injury Lawsuits Report: Summer 2016
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for patients who used the drugs listed below and developed certain side effects. (1)...
View ArticleFarxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet...
View ArticleDecember 2016: FDA Requires Safety Warnings Label Change For Jardiance
After the December 2, 2016 decision by the FDA to expand the health benefits for the relatively new diabetes medicine Jardiance (empagliflozin) to include preventing fatal heart attacks and strokes in...
View ArticleInvokana Has New Warning About Risk Of Lower Limb Amputation In Canada
We continue to monitor the drug safety regulators as well as the medical literature concerning the possible link between an increased risk of these amputations and the use of SGLT2 inhibitors such as...
View ArticleFarxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, “IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER — MDL No. 2776”,...
View ArticleJardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
The June 8, 2017 edition of The New England Journal of Medicine (NEJM) has a “To the Editor” letter, titled “Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor”, which is likely...
View ArticleInvokana Gets “Black-Box Warning” For Risk Of Leg And Foot Amputations
In the final week of July 2017, the FDA issued a notification that it had approved a revised drug label for Invokana and Invokamet, as well as a revised Medication Guide for these two diabetes drugs...
View Article